专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110038842A1 High affinity ny-eso t cell receptor 有权
标题翻译：高亲和力ny-eso细胞受体
公开(公告)号：US20110038842A1
公开(公告)日：2011-02-17
申请号：US11596458
申请日：2005-05-18
申请人： Jonathan Michael Boulter , Bent Karsten Jakobsen , Yi Li , Peter Eamon Molloy , Steven Mark Dunn
发明人： Jonathan Michael Boulter , Bent Karsten Jakobsen , Yi Li , Peter Eamon Molloy , Steven Mark Dunn
IPC分类号： A61K35/12 , C07K14/00 , C07K14/54 , A61P35/00 , C12N5/00 , A61K38/16
CPC分类号： C07K14/7051 , A61K35/12 , A61K38/00 , A61K39/39 , A61K2039/5156 , A61K2039/585 , C07K14/55 , C07K14/705 , C07K19/00 , C07K2319/33 , C07K2319/40 , C07K2319/74
摘要： The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 μM and/or have an off-rate (koff) of 1×10−3 S−1 or slower.
摘要翻译：本发明提供具有与SLLMWITQC-HLA-A * 0201结合的性质的T细胞受体（TCR），所述SLLMWITQC肽衍生自由一系列肿瘤细胞表达的NY-ESO-1蛋白。所述TCR具有小于或等于1μM的肽-HLAI复合物的KD和/或具有1×10 -3 S -1或更低的脱离率（k off）的KD。

2. 发明申请

US20070213345A1 Immuno Inhibitory Pyrazolone Compounds 有权
公开(公告)号：US20070213345A1
公开(公告)日：2007-09-13
申请号：US10577470
申请日：2004-11-02
申请人： Ian Matthews
发明人： Ian Matthews
IPC分类号： A61K31/496 , A61K31/4152 , A61K31/4155 , C07D231/08 , C07D401/08 , C07D403/04 , C07D403/14 , C07D403/08 , C07D401/14 , C07D401/04 , A61K31/454 , A61K31/4545
CPC分类号： C04B35/632 , C07D231/22 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/14
摘要： Compounds of formula (IA) or (IB) are inhibitors of CD80 and useful in immunomodulation therapy: wherein Ar represents an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group having from 5 to 10 ring atoms; R1 and R2 independently represent H, or C1-C6 alkyl; R3 represents H; F; CI; Br, —NO2; —CN; C1-C6 alkyl optionally substituted by F or CI; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR6R7, —NR7C(═O)R6, —NR7C(═O)OR6, —NHC(═O)NR7R6 or —NHC(═S)NR7R6 wherein R6 represents H, or a radical of formula -(Alk)m-Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C1-C12 alkylene, or C2-C12 alkenylene, or C2-C12 alkynylene radical or a divalent C3-C12 carbocyclic radical, any of which radicals may be interrupted by one or more —O—, —S— or —N(R8)— radicals wherein R8 represents H or C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, or C3-C6 cycloalkyl, and Q represents H; —CF3; —OH; —SH; —NR8R8 wherein each R8 may be the same or different, or form a ring when taken together with the nitrogen to which they are attached; an ester group; or an optionally substituted aryl, aryloxy, cycloalkyl, cycloalkenyl or heterocyclic group; and R7 represents H or C1-C6 alkyl; or when taken together with the atom or atoms to which they are attached R6 and R7 form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula -(Z)n-(Alk)- or -(Alk)-(Z)n- wherein Z represents -0-, —S— or —NH—, Alk is as defined in relation to R6 and n is 0 or 1.

3. 发明申请

WO2002077030A3 MODIFIED MHC MOLECULES WHOSE BINDING TO CD8 OR CD4 IS INHIBITED AND USE THEREOF 审中-公开
公开(公告)号：WO2002077030A3
公开(公告)日：2002-10-03
申请号：PCT/GB2002/001499
申请日：2002-03-27
申请人： AVIDEX LIMITED , JAKOBSEN, Bent, Karsten , CAMERON, Brian, John
发明人： JAKOBSEN, Bent, Karsten , CAMERON, Brian, John
IPC分类号： C07K14/74
摘要： The invention provides a method of inhibiting the activity of T cells against a cell presenting molecules of a selected Major Histocompatibility Complex (MHC) type, the method comprising causing the cell to present modified molecules of the selected MHC type whose binding to CD8 or CD4 is inhibited but which can present the same peptide or peptides as unmodified molecules of the MHC type. Such modified molecules are also provided as are nucleic acids encoding them.

4. 发明申请

WO2002077030A2 SUBSTANCES 审中-公开
标题翻译：物质
公开(公告)号：WO2002077030A2
公开(公告)日：2002-10-03
申请号：PCT/GB2002/001499
申请日：2002-03-27
申请人： AVIDEX LIMITED , JAKOBSEN, Bent, Karsten , CAMERON, Brian, John
发明人： JAKOBSEN, Bent, Karsten , CAMERON, Brian, John
IPC分类号： C07K14/74
CPC分类号： C07K14/70539 , A61K38/00
摘要： The invention provides a method of inhibiting the activity of T cells against a cell presenting molecules of a selected Major Histocompatibility Complex (MHC) type, the method comprising causing the cell to present modified molecules of the selected MHC type whose binding to CD8 or CD4 is inhibited but which can present the same peptide or peptides as unmodified molecules of the MHC type. Such modified molecules are also provided as are nucleic acids encoding them.
摘要翻译：本发明提供了一种抑制T细胞抵抗所选择的主要组织相容性复合物（MHC）型分子的细胞的活性的方法，所述方法包括使细胞呈现与CD8或CD4结合的所选择的MHC类型的修饰分子抑制但可以呈现与MHC类型的未修饰分子相同的肽或肽。还提供了这样的修饰分子，就像编码它们的核酸一样。

5. 发明申请

WO2005046679A1 IMMUNO INHIBITORY PYRAZOLONE COMPOUNDS 审中-公开
标题翻译：免疫抑制剂吡唑啉酮化合物
公开(公告)号：WO2005046679A1
公开(公告)日：2005-05-26
申请号：PCT/GB2004/004629
申请日：2004-11-02
申请人： AVIDEX LIMITED , MATTHEWS, Ian, Richard
发明人： MATTHEWS, Ian, Richard
IPC分类号： A61K31/4152
CPC分类号： C04B35/632 , C07D231/22 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/14
摘要： Compounds of formula (IA) or (IB) are inhibitors of CD80 and useful in immunomodulation therapy: wherein Ar represents an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group having from 5 to 10 ring atoms; R 1 and R 2 independently represent H, or C l -C 6 alkyl; R 3 represents H; F; CI; Br; -NO 2 ; - CN; C 1 -C 6 alkyl optionally substituted by F or CI; or C 1 -C 6 alkoxy optionally substituted by F; R 4 represents a carboxylic acid group (-COOH) or an ester thereof, or -C(=O)NR 6 R 7 , -NR 7 C(=O)R 6 , -NR 7 C(=O)OR 6 , -NHC(=O)NR 7 R 6 or -NHC(=S)NR 7 R 6 wherein R 6 represents H, or a radical of formula -(Alk) m -Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C 1 -C 12 alkylene, or C 2 -C 12 alkenylene, or C 2 -C 12 alkynylene radical or a divalent C 3 -C 12 carbocyclic radical, any of which radicals may be interrupted by one or more -0-, -S- or -N(R 8 )- radicals wherein R 8 represents H or C 1 -C 4 alkyl, C 3 -C 4 alkenyl, C 3 -C 4 alkynyl, or C 3 -C 6 cycloalkyl, and Q represents H; -CF 3; -OH; -SH; -NR 8 R 8 wherein each R 8 may be the same or different, or form a ring when taken together with the nitrogen to which they are attached; an ester group; or an optionally substituted aryl, aryloxy, cycloalkyl, cycloalkenyl or heterocyclic group; and R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula -(Z) n -(Alk)- or -(Alk)-(Z) n - wherein Z represents -0-, -S- or -NH-, Alk is as defined in relation to R 6 and n is 0 or 1.
摘要翻译：式（IA）或（IB）的化合物是CD80的抑制剂，可用于免疫调节治疗：其中Ar表示任选取代的具有5至10个环原子的单环或双环芳族或杂芳族基团; R1和R2独立地表示H或C1-C6烷基; R3表示H; F; CI; BR; NO 2; - CN; 任选被F或Cl取代的C 1 -C 6烷基; 或任选被F取代的C 1 -C 6烷氧基; 或-C（= O）NR 6 R 7，-NR 7 C（= O）R 6，-NR 7 C（= O）OR 6，-NHC（= O）NR 7 R 6或-NHC （= S）NR 7 R 6，其中R 6表示H，或式 - （Alk）mQ基团，其中m为0或1，Alk为任选取代的二价直链或支链C 1 -C 12亚烷基或C 2 -C 12亚烯基， C 12亚炔基或二价C 3 -C 12碳环基团，其中任何基团可被一个或多个-O-，-S-或-N（R 8） - 基团中断，其中R 8表示H或C 1 -C 4烷基， C4链烯基，C3-C4炔基或C3-C6环烷基，Q表示H; -CF 3; -OH; -SH; -NR 8 R 8，其中每个R 8可以相同或不同，或者当与它们所连接的氮一起取代时形成环; 酯基; 或任选取代的芳基，芳氧基，环烷基，环烯基或杂环基; 并且R 7表示H或C 1 -C 6烷基; 或者当与它们所连接的原子或原子一起时R6和R7形成具有5,6或7个环原子的单环杂环; 并且X表示式 - （Z）n-（Alk） - 或 - （Alk） - （Z）n-的键或二价基团，其中Z表示-O - ， - S-或-NH-，Alk为关于R6定义，n为0或1。

6. 发明申请

WO2002088740A2 METHOD 审中-公开
标题翻译：方法
公开(公告)号：WO2002088740A2
公开(公告)日：2002-11-07
申请号：PCT/GB2002/001979
申请日：2002-04-30
申请人： AVIDEX LIMITED , JAKOBSEN, Bent, Karsten
发明人： JAKOBSEN, Bent, Karsten
IPC分类号： G01N33/564
CPC分类号： G01N33/6878 , G01N33/564 , G01N2333/70539 , G01N2500/00
摘要： The present invention provides a method for identifying an entity which binds to a peptide-Major Histocompatibility Complex (pMHC) complex. In the method, a pMHC complex is formed between a predetermined MHC and a peptide which is obtained from a protein sequence and is not known to be capable of being complexed with the predetermined MHC. The resulting pMHC is used to screen for an entity which binds to the pMHC complex.
摘要翻译：本发明提供了鉴定结合肽 - 主要组织相容性复合物（pMHC）复合物的实体的方法。在该方法中，在预定的MHC和从蛋白质序列获得的肽之间形成pMHC复合物，并且不知道能够与预定的MHC复合。所得的pMHC用于筛选结合pMHC复合物的实体。

7. 发明申请

US20070191278A1 CD8 AS AN INHIBITOR OF THE CELLULAR IMMUNE SYSTEM 审中-公开
标题翻译： CD8作为细胞免疫系统的抑制剂
公开(公告)号：US20070191278A1
公开(公告)日：2007-08-16
申请号：US11696301
申请日：2007-04-04
申请人： Bent Jakobsen , George Gao , Ulrich Gerth , Andrew Sewell
发明人： Bent Jakobsen , George Gao , Ulrich Gerth , Andrew Sewell
IPC分类号： A61K38/17
CPC分类号： C07K14/70517 , A61K38/00 , C07K2319/00
摘要： This invention is directed to a method for inhibiting cytotoxic T lymphocyte (CTL) activity in which soluble CD8 is used as the inhibitor. The invention is further directed to soluble forms of the CD8 molecule which can be administered to a patient. The method of this invention is particularly useful for immunosuppressive therapy in which inhibition of CTL activity is desirable, for example, in patients undergoing transplantation.
摘要翻译：本发明涉及一种抑制细胞毒性T淋巴细胞（CTL）活性的方法，其中使用可溶性CD8作为抑制剂。本发明还涉及可以给予患者的CD8分子的可溶形式。本发明的方法特别适用于抑制CTL活性的免疫抑制治疗，例如在接受移植的患者中。

8. 发明申请

US20060165707A1 Substances 审中-公开
标题翻译：物质
公开(公告)号：US20060165707A1
公开(公告)日：2006-07-27
申请号：US10480304
申请日：2002-06-19
申请人： Bent Jakobsen , Jonathan Boulter
发明人： Bent Jakobsen , Jonathan Boulter
IPC分类号： A61K39/00 , C07H21/04 , C12P21/06 , C07K14/74 , A61K9/127
CPC分类号： C07K14/70539 , A61K48/00
摘要： The present invention provides a multimers of class I Major Histocompatibility Complexes (MHCs) having a modified P2-microglobulin whose binding to CD8 is inhibited. Such MHCs are capable of inhibiting CD8+ T cell response, particularly by inducing apoptosis or anergy of the T cell. The invention also provides nucleic acids encoding such molecules, and the use of such multimers and nucleic acids in immunosuppressive therapy, in particular as inhibitors of cytotoxic T cell responses.
摘要翻译：本发明提供具有与CD8结合被抑制的经修饰的P2-微球蛋白的I类主要组织相容性复合物（MHC）的多聚体。这样的MHC能够抑制CD8 + T细胞应答，特别是通过诱导T细胞的凋亡或无反应性。本发明还提供编码这种分子的核酸，以及这些多聚体和核酸在免疫抑制治疗中的用途，特别是作为细胞毒性T细胞应答的抑制剂。

9. 发明申请

US20030096432A1 Screening methods 审中-公开
标题翻译：筛选方法
公开(公告)号：US20030096432A1
公开(公告)日：2003-05-22
申请号：US10103597
申请日：2002-03-21
申请人： AVIDEX LIMITED
发明人： Bent Karsten Jakobsen
IPC分类号： G01N033/543
CPC分类号： G01N33/56972 , G01N33/566
摘要： The present invention provides methods for sequentially screening for compounds with the potential to interfere with low affinity receptor-ligand contacts using an interfacial optical assay, such as surface plasmon resonance (SPR). The method comprises contacting a candidate compound with an immobilised receptor, contacting the receptor, which may or may not have the candidate compound bound to it, with the ligand and detecting by interfacial optical assay whether or not the ligand or ligand-compound complex has bound to the receptor or receptor-compound complex. If the ligand binds, the method shows that the compound does not inhibit the receptor-ligand interaction. If the ligand does not bind, the method shows that the compound inhibits the receptor-ligand interaction. The method is particularly usefull for screening for inhibitors of the interaction between MHC/peptide complex and T cell receptor, MHC/peptide complex and CD8 coreceptor or MHC/peptide complex and CD4 coreceptor.
摘要翻译：本发明提供了使用界面光学测定法（例如表面等离子体共振（SPR））依次筛选具有干扰低亲和力受体 - 配体接触的潜能的化合物的方法。该方法包括使候选化合物与固定化的受体接触，使与受体结合的候选化合物的受体与配体接触，并通过界面光学测定法检测配体或配体 - 化合物复合物是否结合受体或受体复合物。如果配体结合，则该方法显示该化合物不抑制受体 - 配体相互作用。如果配体不结合，则该方法显示该化合物抑制受体 - 配体相互作用。该方法特别适用于筛选MHC /肽复合物和T细胞受体，MHC /肽复合物和CD8共同受体或MHC /肽复合物和CD4共受体之间的相互作用的抑制剂。

10. 发明申请

US20100047220A1 Substances 有权
标题翻译：物质
公开(公告)号：US20100047220A1
公开(公告)日：2010-02-25
申请号：US11597252
申请日：2005-06-29
申请人： Bent Karsten Jakobsen
发明人： Bent Karsten Jakobsen
IPC分类号： A61K35/12 , C12N5/0783 , A61P35/00 , A61P31/00 , A61P37/00 , A61P25/00 , A61P3/00 , A61P19/02
CPC分类号： C12N15/85 , A61K35/17 , C07K14/7051 , C12N5/0636 , C12N2510/00
摘要： This invention provides a cell presenting at least one T cell receptor (TCR) anchored to the membrane by a transmembrane sequence, said TCR comprising an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs.
摘要翻译：本发明提供了通过跨膜序列锚定于膜的至少一种T细胞受体（TCR）的细胞，所述TCR在天然TCR中不存在的胞外恒定结构域残基之间包含链间二硫键。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式